Marginal Zone Lymphoma Mzl clinical trials

Explore recruiting marginal zone lymphoma mzl clinical trials.

Recruiting marginal zone lymphoma mzl studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Marginal Zone Lymphoma Mzl trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A PHASE 2, OPEN-LABEL, SINGLE-ARM, MULTICOHORT, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF JCAR017 IN ADULT SUBJECTS WITH RELAPSED OR REFRACTORY INDOLENT B-CELL NON-HODGKIN LYMPHOMA (NHL) (Transcend FL)

Sweden, France, Spain, Austria, Germany, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma

Czechia, Norway, Netherlands, Sweden, France, Belgium +10 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Open Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Combination with Lenalidomide Versus Rituximab in Combination with Lenalidomide in Relapsed/Refractory Participants with Follicular Lymphoma and Marginal Zone Lymphoma (OLYMPIA-5)

Spain, Czechia, Poland, Austria, Germany, Belgium +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

VALYM - A phase II open-label study evaluating valemetostat tosylate as a single agent in patients with relapse/refractory B-cell lymphoma

France, Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab With or Without Acalabrutinib in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or is Refractory to Rituximab

Spain, Germany

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A pivotal phase 3 clinical trial to assess the diagnostic performance and safety of [68Ga]Ga-PentixaFor ([68Ga]Ga-PTF), a positron emission tomography (PET) imaging agent, versus [18F]FDG PET/CT imaging, for staging of patients with confirmed marginal zone lymphoma (MZL) exemplary for CXCR4-positive malignant lymphomas: a prospective, international, multi-center, comparative, randomized, cross-over, open-label lymphoma diagnostic trial (LYMFOR).

Germany, Italy, Spain, France, Austria

Therapeutic confirmatory (Phase III) EU CTIS Study details

Marginal Zone Lymphoma Mzl trials by city

Marginal Zone Lymphoma Mzl in Toronto Marginal Zone Lymphoma Mzl in Vancouver Marginal Zone Lymphoma Mzl in Montreal Marginal Zone Lymphoma Mzl in Calgary Marginal Zone Lymphoma Mzl in Edmonton Marginal Zone Lymphoma Mzl in Ottawa Marginal Zone Lymphoma Mzl in Winnipeg Marginal Zone Lymphoma Mzl in Quebec City Marginal Zone Lymphoma Mzl in Hamilton Marginal Zone Lymphoma Mzl in Kitchener Marginal Zone Lymphoma Mzl in London Marginal Zone Lymphoma Mzl in Halifax Marginal Zone Lymphoma Mzl in New York Marginal Zone Lymphoma Mzl in Los Angeles Marginal Zone Lymphoma Mzl in Chicago Marginal Zone Lymphoma Mzl in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease